



PATENT
Docket No. GZ 2098.00

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 19 2002

In re Application for:

Charles A. NICOLETTE

Serial No.: 10/077,629

Filing Date: February 14, 2002

For: ALTERED PEPTIDE LIGANDS

Examiner: Not Yet Assigned

Group Art Unit: 1645

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached forms PTO-1449a and PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- ☐ Within three months of the application filing date or before receipt of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☒ Before the mailing date of the first Office Action on the merits. In the event, however that an Office Action has crossed in the mail with this Information Disclosure

Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

- ☐ After receipt of a first Office Action on the merits but before a final Office Action or Notice of Allowance. A fee is required. The Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
- ☐ After receipt of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Certification under 37 C.F.R. § 1.97(e) is provided herein. The Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

The undersigned certifies that:

- ☐ Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols,

results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 50-1178 referencing 19442-7250. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: June 11, 2002

By: Antoinette F. Konski

Antoinette F. Konski
Registration No. 34,202

McCutchen Doyle Brown & Enersen LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111-4067
Telephone: (650) 849-4950
Facsimile: (650) 849-4800

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/077,629
Filing Date	February 14, 2002
First Named Inventor	Charles A. NICOLETTE
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2098.00

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner's Signature	Date Considered
-------------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must

precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. CMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/077,629
Filing Date	February 14, 2002
First Named Inventor	Charles A. NICOLETTE
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	GZ 2098.00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	Y
	1	SINKOVICS, J.G. and HORVATH, J.C. "Vaccination against human cancers (review)" <i>Int. J. Oncol.</i> (2000) 16(1):81-96	
	2	WEINER, L.M. "Monoclonal antibody therapy of cancer" <i>Semin. Oncol.</i> (October 1999) 26:43-51	
	3	ROSELLI, M. et al. "Tumor markers as targets for selective diagnostic and therapeutic procedures" <i>Anticancer Res.</i> (1996) 16(4B):2187-2192	
	4	TRAIL, P.A. and BIANCHI, A.B. "Monoclonal antibody drug conjugates in the treatment of cancer" <i>Cancer</i> (1999) 11(5):584-588	
	5	FAGERBERG, J. et al. "Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients" <i>PNAS USA</i> (May 1995) 92(11):4773-4777	
	6	KAWAKAMI, Y. et al. "Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor" <i>PNAS USA</i> (April 1994) 91(9):3515-3519	
	7	ENGLEHARD, V.H. "Structure of peptides associated with Class I and Class II MHC molecules" <i>Annu. Rev. Immunol.</i> (1994) 12:181-207	
	8	RAMMENSEE, H-G. et al. "Peptides naturally presented by MHC Class I molecules" <i>Annu. Rev. Immunol.</i> (1993) 11:213-244	
	9	HUNT, D.F. et al. "Characterization of peptides bound to the Class I MHC molecule HLA-A2.1 by mass spectrometry" <i>Science</i> (March 1992) 255:1261-1263	
	10	UDAKA, K. et al. "A naturally occurring peptide recognized by alloreactive CD8 ⁺ cytotoxic T lymphocytes in association with a Class I MHC protein" <i>Cell</i> (June 1992) 69:989-998	
	11	VAN DE WAL, Y. et al. "Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin" <i>PNAS USA</i> (August 1998) 95:10050-10054	
	12	LAMB, J.R. et al. "A novel approach to the identification of T-cell epitopes in <i>Mycobacterium tuberculosis</i> using human T-lymphocyte clones" <i>Immunology</i> (1987) 60:1-5	
	13	BOON, T. et al. "Tumor antigens recognized by T lymphocytes" <i>Annu. Rev. Immunol.</i> (1994) 12:337-365	
	14	NEOPHYTOU, P.I. et al. "T-cell epitope analysis using subtracted expression libraries (TEASEL): application to a 38-kDa autoantigen recognized by T cells from an insulin-dependent diabetic patient" <i>PNAS USA</i> (March 1996) 93:2014-2018	
	15	GAVIN, M.A. et al. "Major histocompatibility complex class I allele-specific peptide libraries: identification of peptides that mimic an H-Y T cell epitope" <i>Eur. J. Immunol.</i> (1994) 24:2124-2133	
	16	GUNDLACH, B.R. et al. "Determination of T cell epitopes with random peptide libraries" <i>J. Immunol. Meth.</i> (1996) 192:149-155	
	17	BLAKE, J. et al. "Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC Class I-restricted cytolytic T lymphocytes" <i>J. Exp. Med.</i> (July 1996) 184:121-130	
	18	HIEMSTRA, H.S. et al. "The identification of CD4 ⁺ T cell epitopes with dedicated synthetic peptide libraries" <i>PNAS USA</i> (September 1997) 94:10313-10318	
	19	HEMMER, B. et al. "Identification of high potency microbial and self ligands for a human autoreactive Class II-restricted T cell clone" <i>J. Exp. Med.</i> (May 1997) 185(9):1651-1659	
	20	CHEN, Y-Z. et al. "Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide" <i>J. Immunol.</i> (1996) 157:3783-3790	
	21	STRAUSBAUCH, M.A. et al. "Identification of mimotopes for the H4 minor histocompatibility antigen" <i>Intl. Immunol.</i> (1998) 10(4):421-434	

RECEIVED
JUN 19 2002
TECH CENTER 1600/2000

